```html

Exogenous Cushing Syndrome – A Complete Patient Guide

Overview

Exogenous Cushing syndrome is a form of hypercortisolism that results from prolonged exposure to high levels of glucocorticoid (steroid) medications taken for other medical conditions. Unlike endogenous Cushing syndrome, where the body itself over‑produces cortisol, exogenous Cushing syndrome is iatrogenic—caused by a medical treatment.

The condition can affect anyone who uses glucocorticoids for a long period, but it is most common among:

• Adults with chronic inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, lupus, inflammatory bowel disease).
• Patients receiving long‑term high‑dose steroids after organ transplantation.
• Individuals with asthma or chronic obstructive pulmonary disease (COPD) who rely on oral or injectable steroids.

According to the CDC and Mayo Clinic, up to 5 % of patients on chronic glucocorticoid therapy develop clinical features of Cushing syndrome, making it the most common cause of iatrogenic hypercortisolism worldwide.

Symptoms

Symptoms develop gradually and may be subtle at first. The classic “cushion‑like” appearance is a hallmark, but many patients present with a combination of metabolic, musculoskeletal, dermatologic, and neuro‑psychiatric signs.

Physical signs

• Central (truncal) obesity – increased fat around the abdomen, “moon face,” and a fatty “buffalo hump” on the upper back.
• Thin skin – easy bruising, especially on the arms and legs; skin may appear translucent.
• Purple or pink striae – stretch marks on the abdomen, breasts, thighs, or arms that are wider than 1 cm.
• Facial rounding – “moon face” due to fat deposition.
• Muscle weakness – proximal muscle wasting, especially in the thighs and upper arms (often mistaken for age‑related sarcopenia).
• Hirsutism & acne – excess facial or body hair and oily skin, especially in women.
• Bone loss – increased risk of osteoporosis and vertebral compression fractures.

Metabolic & systemic signs

• Hyperglycemia or new‑onset type 2 diabetes.
• Hypertension (high blood pressure).
• Elevated triglycerides and dyslipidemia.
• Weight gain despite unchanged diet.
• Fatigue, generalized malaise, and decreased exercise tolerance.

Neuro‑psychiatric manifestations

• Mood swings, irritability, anxiety, or depression.
• Memory problems and difficulty concentrating (“brain fog”).
• Sleep disturbances, including insomnia.

Reproductive effects

• Irregular menstrual cycles or amenorrhea in women.
• Decreased libido and erectile dysfunction in men.

Causes and Risk Factors

Exogenous Cushing syndrome is directly linked to the type, dose, route, and duration of glucocorticoid therapy.

Common sources of excess glucocorticoids

• Oral prednisone, prednisolone, methylprednisolone – most frequent cause.
• Intravenous (IV) or intramuscular (IM) bolus injections – for severe flares of asthma, rheumatologic disease, or allergic reactions.
• Topical or inhaled steroids – high‑potency preparations used chronically can contribute, especially in children.
• Biologic agents that increase endogenous cortisol – rare but documented (e.g., ACTH‑releasing hormone analogues).

Risk factors that increase susceptibility

• Higher cumulative glucocorticoid dose (> 5 g prednisone equivalent per year).
• Long‑term therapy (> 3 months) without tapering.
• Concomitant use of drugs that inhibit cortisol metabolism (e.g., ketoconazole, certain antifungals).
• Pre‑existing metabolic syndrome, diabetes, or hypertension.
• Genetic variation in glucocorticoid receptor sensitivity (rare).

Diagnosis

Because the source of excess cortisol is known (exogenous steroids), the diagnostic focus is on confirming clinical Cushing‑like features, assessing severity, and ruling out adrenal suppression.

Clinical assessment

• Detailed medication history – dose, duration, formulation.
• Physical exam looking for classic signs (central obesity, striae, skin changes).

Laboratory tests

• Morning serum cortisol – usually low or suppressed due to feedback inhibition, confirming exogenous source.
• ACTH level – typically low or undetectable.
• 24‑hour urinary free cortisol (UFC) – low or normal, helps differentiate from endogenous Cushing.
• Blood glucose, HbA1c, lipid panel – to gauge metabolic impact.
• Bone density (DEXA) scan – baseline assessment for osteoporosis.

Imaging (only when needed)

If adrenal insufficiency is suspected after steroid withdrawal, an MRI of the pituitary or CT of the adrenals may be ordered to evaluate atrophy.

Guidelines

The Endocrine Society’s clinical practice guideline (2022) recommends confirming suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis before tapering high‑dose steroids, using a low‑dose ACTH stimulation test if needed.

Treatment Options

The cornerstone of therapy is reduction or cessation of the offending glucocorticoid while managing the physiologic consequences.

1. Gradual steroid taper

• Never stop long‑term steroids abruptly; tapering prevents adrenal crisis.
• A typical taper reduces the dose by 10 %–20 % every 1–2 weeks, adjusted for symptoms and cortisol levels.
• Consult the prescribing specialist (rheumatology, pulmonology, etc.) to substitute disease‑modifying agents if possible.

2. Alternate‑day or “bridge” therapy

When disease control is essential, clinicians may switch to alternate‑day dosing or add a non‑steroidal immunomodulator (e.g., methotrexate, azathioprine, biologics) to allow lower steroid doses.

3. Medications to control comorbidities

• Antihypertensives – ACE inhibitors, ARBs, thiazide diuretics.
• Antidiabetic agents – metformin, SGLT2 inhibitors, or insulin if needed.
• Lipid‑lowering therapy – statins.
• Bone protective agents – calcium, vitamin D, bisphosphonates (alendronate, risedronate), or denosumab for high‑risk patients.

4. Lifestyle interventions

Dietary modifications, regular exercise, and weight management help mitigate metabolic sequelae and improve mood.

5. Managing adrenal insufficiency

If the HPA axis remains suppressed after taper, patients may need temporary “stress‑dose” steroids during surgery, illness, or trauma. Education on emergency hydrocortisone injection kits is essential.

Living with Exogenous Cushing Syndrome

Adapting daily life while tapering steroids can be challenging. Below are practical strategies.

Medication management

• Keep a medication diary—record dose, timing, and side effects.
• Set alarms for taper steps and for “stress‑dose” steroids.
• Carry a steroid card or medical alert bracelet indicating current steroid regimen.

Nutrition

• Follow a balanced, low‑sodium, high‑fiber diet to control blood pressure and blood sugar.
• Limit processed foods high in saturated fat and added sugars.
• Ensure adequate calcium (1,200 mg) and vitamin D (800–1,000 IU) intake.

Physical activity

• Aim for at least 150 minutes of moderate aerobic activity per week (e.g., brisk walking, cycling).
• Incorporate resistance training 2–3 times weekly to preserve muscle mass.
• Start slowly; consult a physical therapist if severe muscle weakness is present.

Stress & mental health

• Practice stress‑reduction techniques—mindfulness, yoga, or deep‑breathing.
• Seek counseling or support groups if depression or anxiety emerges.
• Keep a sleep hygiene routine: consistent bedtime, dark bedroom, limit caffeine.

Monitoring

• Schedule regular follow‑up visits every 3–6 months during taper.
• Track blood pressure, weight, and glucose at home when possible.
• Repeat bone density testing every 1–2 years if risk factors are present.

Prevention

Because exogenous Cushing syndrome is iatrogenic, prevention revolves around judicious steroid prescribing and patient education.

• Prescribe the lowest effective dose for the shortest duration possible.
• Consider steroid‑sparing agents early in chronic inflammatory diseases.
• Educate patients on the risks of over‑the‑counter steroid creams or “quick‑fix” injections.
• Implement regular review of chronic steroid therapy by a multidisciplinary team.
• Use inhaled or topical steroids with low systemic bioavailability when appropriate.

Complications

If unaddressed, prolonged hypercortisolism can lead to serious, potentially irreversible health problems.

• Cardiovascular disease – accelerated atherosclerosis, myocardial infarction, stroke.
• Type 2 diabetes mellitus – may become insulin‑dependent.
• Osteoporosis and fractures – especially vertebral compression fractures.
• Infections – immunosuppression raises susceptibility to bacterial, viral, and fungal infections.
• Psychiatric disorders – major depression, psychosis, or severe anxiety.
• Adrenal insufficiency after abrupt steroid withdrawal, which can be life‑threatening.
• Skin changes – poor wound healing, easy bruising, and increased risk of cellulitis.

When to Seek Emergency Care

---

Sources: Mayo Clinic. Exogenous Cushing syndrome. mayoclinic.org; CDC. Steroid Use and Safety. cdc.gov; Endocrine Society Clinical Practice Guideline 2022; NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); WHO. Guidelines on the Use of Corticosteroids.

```